Impact of glibenclamide pretreatment on outcomes in acute ischemic stroke patients with type 2 diabetes: a retrospective case-control study
Abstract Ischemic stroke is a major health concern, particularly in patients with type 2 diabetes mellitus (T2DM), who are at elevated risk. This study aimed to evaluate the prognostic impact of glibenclamide pretreatment on patients with acute ischemic stroke and T2DM. A total of 122 patients with...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-15764-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226258560319488 |
|---|---|
| author | Kaimin Xiao Ji Tang Xinwei Yang Hongmei Chen Ping Liu Rongxin He Lihui Xie Heling Chu Yuping Tang Li Chen |
| author_facet | Kaimin Xiao Ji Tang Xinwei Yang Hongmei Chen Ping Liu Rongxin He Lihui Xie Heling Chu Yuping Tang Li Chen |
| author_sort | Kaimin Xiao |
| collection | DOAJ |
| description | Abstract Ischemic stroke is a major health concern, particularly in patients with type 2 diabetes mellitus (T2DM), who are at elevated risk. This study aimed to evaluate the prognostic impact of glibenclamide pretreatment on patients with acute ischemic stroke and T2DM. A total of 122 patients with acute ischemic stroke and T2DM were retrospectively analyzed. Based on medication history, patients were categorized into the glibenclamide group (group 1, n = 54) and the control group (group 2, n = 68). Stroke severity at admission was assessed using the National Institutes of Health Stroke Scale (NIHSS), and functional status was evaluated with the Barthel Index (BI) and modified Rankin Scale (mRS). Patients were followed for 3 months. At admission, group 1 demonstrated significantly better neurological function (lower NIHSS) and higher BI scores compared to group 2 (P < 0.05). At 3 months, mortality was 1.9% in group 1 and 5.9% in group 2, though this difference was not statistically significant (χ2 = 0.430, P = 0.512). Adverse events occurred in 7.4% and 10.3% of patients in groups 1 and 2, respectively (P > 0.05), with no drug-related deaths or serious safety concerns. The incidence of hemorrhagic transformation also showed no significant difference (P > 0.05). However, group 1 showed significantly better functional outcomes at 3 months, with higher BI scores and lower mRS scores (P < 0.05), suggesting improved independence and neurological recovery. Glibenclamide pretreatment in patients with acute ischemic stroke and T2DM may confer clinical benefits by reducing stroke severity and enhancing post-stroke functional outcomes, without increasing adverse events. |
| format | Article |
| id | doaj-art-1aa308eb05b5437f98733ab1b0721d1d |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-1aa308eb05b5437f98733ab1b0721d1d2025-08-24T11:28:55ZengNature PortfolioScientific Reports2045-23222025-08-011511710.1038/s41598-025-15764-5Impact of glibenclamide pretreatment on outcomes in acute ischemic stroke patients with type 2 diabetes: a retrospective case-control studyKaimin Xiao0Ji Tang1Xinwei Yang2Hongmei Chen3Ping Liu4Rongxin He5Lihui Xie6Heling Chu7Yuping Tang8Li Chen9Chengdu University of Traditional Chinese MedicineDepartment of Neurology, People’s Hospital of Ganxian DistrictChengdu University of Traditional Chinese MedicineChengdu University of Traditional Chinese MedicineChengdu University of Traditional Chinese MedicineDepartment of Neurology, The Affiliated Minzu Hospital of Guangxi medical universityDepartment of Neurology, People’s Hospital of Ganxian DistrictDepartment of Gerontology, Shanghai Jiao Tong University Affiliated Sixth People’s HospitalDepartment of Neurology, Huashan Hospital, Fudan UniversityDepartment of Neurology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical UniversityAbstract Ischemic stroke is a major health concern, particularly in patients with type 2 diabetes mellitus (T2DM), who are at elevated risk. This study aimed to evaluate the prognostic impact of glibenclamide pretreatment on patients with acute ischemic stroke and T2DM. A total of 122 patients with acute ischemic stroke and T2DM were retrospectively analyzed. Based on medication history, patients were categorized into the glibenclamide group (group 1, n = 54) and the control group (group 2, n = 68). Stroke severity at admission was assessed using the National Institutes of Health Stroke Scale (NIHSS), and functional status was evaluated with the Barthel Index (BI) and modified Rankin Scale (mRS). Patients were followed for 3 months. At admission, group 1 demonstrated significantly better neurological function (lower NIHSS) and higher BI scores compared to group 2 (P < 0.05). At 3 months, mortality was 1.9% in group 1 and 5.9% in group 2, though this difference was not statistically significant (χ2 = 0.430, P = 0.512). Adverse events occurred in 7.4% and 10.3% of patients in groups 1 and 2, respectively (P > 0.05), with no drug-related deaths or serious safety concerns. The incidence of hemorrhagic transformation also showed no significant difference (P > 0.05). However, group 1 showed significantly better functional outcomes at 3 months, with higher BI scores and lower mRS scores (P < 0.05), suggesting improved independence and neurological recovery. Glibenclamide pretreatment in patients with acute ischemic stroke and T2DM may confer clinical benefits by reducing stroke severity and enhancing post-stroke functional outcomes, without increasing adverse events.https://doi.org/10.1038/s41598-025-15764-5Acute ischemic strokeGlibenclamideType 2 diabetes mellitusOutcome |
| spellingShingle | Kaimin Xiao Ji Tang Xinwei Yang Hongmei Chen Ping Liu Rongxin He Lihui Xie Heling Chu Yuping Tang Li Chen Impact of glibenclamide pretreatment on outcomes in acute ischemic stroke patients with type 2 diabetes: a retrospective case-control study Scientific Reports Acute ischemic stroke Glibenclamide Type 2 diabetes mellitus Outcome |
| title | Impact of glibenclamide pretreatment on outcomes in acute ischemic stroke patients with type 2 diabetes: a retrospective case-control study |
| title_full | Impact of glibenclamide pretreatment on outcomes in acute ischemic stroke patients with type 2 diabetes: a retrospective case-control study |
| title_fullStr | Impact of glibenclamide pretreatment on outcomes in acute ischemic stroke patients with type 2 diabetes: a retrospective case-control study |
| title_full_unstemmed | Impact of glibenclamide pretreatment on outcomes in acute ischemic stroke patients with type 2 diabetes: a retrospective case-control study |
| title_short | Impact of glibenclamide pretreatment on outcomes in acute ischemic stroke patients with type 2 diabetes: a retrospective case-control study |
| title_sort | impact of glibenclamide pretreatment on outcomes in acute ischemic stroke patients with type 2 diabetes a retrospective case control study |
| topic | Acute ischemic stroke Glibenclamide Type 2 diabetes mellitus Outcome |
| url | https://doi.org/10.1038/s41598-025-15764-5 |
| work_keys_str_mv | AT kaiminxiao impactofglibenclamidepretreatmentonoutcomesinacuteischemicstrokepatientswithtype2diabetesaretrospectivecasecontrolstudy AT jitang impactofglibenclamidepretreatmentonoutcomesinacuteischemicstrokepatientswithtype2diabetesaretrospectivecasecontrolstudy AT xinweiyang impactofglibenclamidepretreatmentonoutcomesinacuteischemicstrokepatientswithtype2diabetesaretrospectivecasecontrolstudy AT hongmeichen impactofglibenclamidepretreatmentonoutcomesinacuteischemicstrokepatientswithtype2diabetesaretrospectivecasecontrolstudy AT pingliu impactofglibenclamidepretreatmentonoutcomesinacuteischemicstrokepatientswithtype2diabetesaretrospectivecasecontrolstudy AT rongxinhe impactofglibenclamidepretreatmentonoutcomesinacuteischemicstrokepatientswithtype2diabetesaretrospectivecasecontrolstudy AT lihuixie impactofglibenclamidepretreatmentonoutcomesinacuteischemicstrokepatientswithtype2diabetesaretrospectivecasecontrolstudy AT helingchu impactofglibenclamidepretreatmentonoutcomesinacuteischemicstrokepatientswithtype2diabetesaretrospectivecasecontrolstudy AT yupingtang impactofglibenclamidepretreatmentonoutcomesinacuteischemicstrokepatientswithtype2diabetesaretrospectivecasecontrolstudy AT lichen impactofglibenclamidepretreatmentonoutcomesinacuteischemicstrokepatientswithtype2diabetesaretrospectivecasecontrolstudy |